# HIV Clinical Pharmacology & Therapeutics Research Training Program

> **NIH NIH D43** · STATE UNIVERSITY OF NEW YORK AT BUFFALO · 2022 · $281,953

## Abstract

This is a renewal application for a D43 titled, HIV Clinical Pharmacology and Therapeutics Research Training
(HIVRT) program led by the University at Buffalo (UB) and the University of Zimbabwe (UZ). Optimizing HIV
prevention of transmission with HIV PReP and treatment as prevention (TasP) to meet 95-95-95 and “ending
the epidemic” strategies. However, successful use of these approaches requires that continued research be
conducted to guide implementation in low-middle income countries. The HIVRT will increase the number of
qualified investigators to seek external funding for this research effort. With the introduction of tenofovir,
lamivudine and dolutegravir, long-acting ARVs (e.g., cabotegravir, rilpivirine), new ARVs (e.g., lenacapavir,
islatravir) and HIV-1 broadly neutralizing antibodies (bNABs), clinical and translational research related to these
new therapeutic agents is needed to examine the optimal pharmacokinetics-pharmacodynamics parameters that
will prevent transmission and/or sustain viral load suppression as well as safety in the context of co-morbidities.
Training of clinician-scientists and translational scientists will utilize the foundation that has been built by the prior
UB-UZ HIVRT and transition to the newly designed research training program. Specific Aims: 1) Provide a HIVRT
for pre-doctoral (5) and post-doctoral (5) trainees that increases the number of researchers with independent,
funded programs with a focus on HIV clinical pharmacology and therapeutics and regional public health priorities
including COVID-19, 2) Mentor HIVRT trainees in team science and that include others with expertise in
pharmaceutical bioanalysis, biomedical informatics, data sciences, genomics, and microbiome, 3) Foster
community support group engagement to participate in innovative research to study novel HIV clinical
pharmacology and therapeutics strategies for prevention and treatment and investigate long-acting
antiretrovirals and monoclonal antibodies and traditional medicines, and 4) Provide an HIVRT that fosters smart
academic-public-private partnerships aimed at addressing sustainable developmental goals. Trainees will have
intensive training at UB during which new knowledge and skills will allow formulation of a research project that
will be conducted under continued supervision for 18 months at UZ for a total of two years of training. The
program will build on our prior Fogarty International Center HIV Research Training program, and an earlier
AITRP. These research training programs provide the foundation for this D43 renewal that includes an
outstanding group of UZ and UB mentors who will provide mentoring and collaboration utilizing the HIV Clinical
Pharmacology and Therapeutics foundation that has been built for HIV clinical and translational research. The
curriculum will be organized and provided through an established Research and Education Training Core. The
D43 has an outstanding external Training Advisory Committee that will c...

## Key facts

- **NIH application ID:** 10473158
- **Project number:** 2D43TW010313-06
- **Recipient organization:** STATE UNIVERSITY OF NEW YORK AT BUFFALO
- **Principal Investigator:** Charles Enos Chiedza Maponga
- **Activity code:** D43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $281,953
- **Award type:** 2
- **Project period:** 2016-04-01 → 2027-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10473158

## Citation

> US National Institutes of Health, RePORTER application 10473158, HIV Clinical Pharmacology & Therapeutics Research Training Program (2D43TW010313-06). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10473158. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*